Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1
Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1 (March 29, 2023) | By Ana Mulero. Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B (March 28, 2023) | By Rosemary Scott. Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and
With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy
With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy (March 21, 2023) | By Tristan Manalac. Monday, BioNTech inked an exclusive worldwide license and collaboration agreement with Maryland-based biopharma
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs Collaboration will leverage CHARM’s DragonFold deep learning platform to identify compounds against targets
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of
MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders
MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders-Seventure etc (February 17, 2023) | By Maat Pharma SA. MaaT Pharma Completes a Capital
Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs
Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs (February 16, 2023) | By Katherine Lewin, News Reporter. Merck is betting on Aqilion’s work on a small molecule inhibitor
Atomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable Diseases
Atomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable Diseases (January 25, 2023) | By BUSINESS WIRE. SAN FRANCISCO — (BUSINESS
BIOHM Raises $7.5 Million to Accelerate Microbiome Research, Artificial Intelligence Capabilities and Product Development
BIOHM Raises $7.5 Million to Accelerate Microbiome Research, Artificial Intelligence Capabilities and Product Development (January 12, 2023) | By BIOHM Health. The funding round, led by Middleland Capital’s VTC Ventures,
Battelle, AmplifyBio, Andelyn team up NIH contract targeting stroke, neurological disease
Battelle, AmplifyBio, Andelyn team up NIH contract targeting stroke, neurological disease (January 10, 2023) | By Carrie Ghose – Staff reporter. A team comprising Battelle and two Central Ohio biotech